Pfizer Reports Fourth-Quarter Earnings Beat and Advances Monthly Obesity Injection

2026-02-03

The BareStory

Pfizer reported fourth-quarter financial results on Tuesday that exceeded analyst expectations, despite posting a net loss of $1.65 billion. The pharmaceutical company announced revenue of $17.56 billion, a decrease of approximately 1% compared to the same period the previous year. Management attributed the revenue decline primarily to lower demand for its Covid-19 vaccine and antiviral pill, Paxlovid. While adjusted earnings per share reached 66 cents, the net loss marked a shift from the net income recorded a year prior.

Alongside its earnings, Pfizer released data from a mid-stage trial of its experimental obesity drug, PF'3944. The company stated that the ultra-long-acting GLP-1 injection, acquired through the purchase of biotech firm Metsera, resulted in up to 12.3% weight loss by week 28. According to the trial results, patients who transitioned from weekly to monthly doses did not experience a weight loss plateau. Pfizer indicated that it plans to advance 10 phase three trials for the injection this year, positioning it as a potential monthly treatment option.

The company reaffirmed its financial guidance for 2026, projecting adjusted profits between $2.80 and $3.00 per share. Pfizer noted that this outlook factors in anticipated sales declines from products losing market exclusivity and the impact of a drug pricing agreement with President Donald Trump. The company stated the deal involves providing deep discounts to Medicaid and guaranteed "most-favored-nation" pricing for new drugs in exchange for a three-year exemption from tariffs. Additionally, Pfizer is proceeding with initiatives to cut costs by approximately $7.7 billion by the end of 2027.

Left Perspective

Strong pipeline progress
Resilient financial performance
Strategic cost and trade management

Right Perspective

Concerns over net losses and revenue decline
Impact of pricing concessions and exclusivity loss
Reliance on cost-cutting measures

Left Perspective

• Strong pipeline progress The company’s advancement of its experimental obesity drug, PF'3944, represents a significant opportunity for future growth. Data from the mid-stage trial showed up to 12.3% weight loss, and the ability to transition patients to monthly dosing without hitting a plateau positions the drug as a viable monthly treatment option. Pfizer plans to capitalize on this by advancing 10 phase three trials this year.

• Resilient financial performance Despite the expected decline in demand for Covid-19 products, the company demonstrated financial resilience by exceeding analyst expectations for the fourth quarter. Adjusted earnings per share remained solid at 66 cents, and management felt confident enough to reaffirm its profit guidance for 2026, projecting adjusted profits between $2.80 and $3.00 per share.

• Strategic cost and trade management Management is taking active steps to secure the company's financial future through significant efficiency measures and strategic agreements. Pfizer is proceeding with initiatives to cut costs by roughly $7.7 billion by 2027. Furthermore, the company has secured a three-year exemption from tariffs through a deal with President Trump, mitigating potential trade risks.

Right Perspective

• Concerns over net losses and revenue decline The shift from net income in the previous year to a reported net loss of $1.65 billion raises concerns about the company's current profitability. Revenue declined by approximately 1%, driven largely by falling demand for the Covid-19 vaccine and the antiviral pill, Paxlovid, indicating that the post-pandemic market adjustment continues to weigh heavily on the bottom line.

• Impact of pricing concessions and exclusivity loss The financial outlook faces headwinds from both regulatory pressures and the product lifecycle. The reaffirmed guidance has to factor in anticipated sales declines from products that are losing market exclusivity. Additionally, the deal with President Trump involves providing deep discounts to Medicaid and guaranteeing "most-favored-nation" pricing for new drugs, which places constraints on future pricing power.

• Reliance on cost-cutting measures To meet its financial targets, the company appears to be relying heavily on reducing expenses rather than solely on organic revenue growth. The plan involves a massive reduction in costs, targeting approximately $7.7 billion in cuts by the end of 2027, suggesting that maintaining profitability will require significant contraction in spending.

How it may affect me

As a U.S. reader:

• Patients seeking weight loss treatments may eventually have access to a monthly injection option as Pfizer moves its experimental drug, which showed significant efficacy, into final testing stages.

• Medicaid recipients could benefit from deep discounts on medications following a negotiated deal between Pfizer and President Trump that includes specific pricing concessions.

• New drugs brought to market might be subject to "most-favored-nation" pricing guarantees, potentially limiting the costs consumers face for future innovative treatments.

• The prices of Pfizer products are unlikely to be affected by import levies for the next three years, as the company secured an exemption from tariffs.

Pfizer Reports Fourth-Quarter Earnings Beat and Advances Monthly Obesity Injection

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at